|
|
Poll Results
Which insulins do you or your child use?
Vote for all that apply
Short acting insulins
Humalog
26%
264
NovoLog/Novorapid
26%
261
Regular/Actrapid/Velosulin
2%
29
Long acting insulins
NPH/Isophane/Insulatard
16%
162
Lente
1%
14
Ultralente
1%
17
Lantus
21%
215
Other
Premixed (70/30, etc.)
1%
19
Other insulin
1%
11
Don't use insulin
1%
4
Total votes: 996
Which insulins do you or your child use?
Poll dates: January 18 - 25, 2004
Total Votes: 996Insulin users today have a great variety of products from which to choose. In the past few years, two fast-acting analogs (Humalog and NovoLog) and one long-acting analog (Lantus) have been introduced and have changed the way many people use insulin. The use of Regular insulin among our readers has dropped off to two percent. NPH use has dropped too, from 32% in 2000 to 16% in 2004.
This table shows readers' answers to this survey over the past four years:
Percentages based on use compared with all responses
Answer Jan 2004 Jan 2003 Jan 2002 Mar 2000 Short acting insulins Humalog 26% 34% 37% 35% NovoLog 26% 12% 3% -- Regular 2% 3% 4% 12% Long acting insulins NPH 16% 22% 28% 32% Lente 1% 1% 3% 4% Ultralente 1% 2% 5% 7% Lantus 21% 17% 11% -- Other Premixed 1% 2% 2% 5% Other insulin 1% 2% 2% 2% Looking at answers in the short-acting and long-acting insulins shows a dramatic change since 2000. The following graphs illustrate the rapid increase in use of insulin analogs and the concurrent decline in the use of Regular and NPH.
Rapid Acting Insulin Use
The rise in the use of NovoLog has been particularly significant since it was introduced in 2002. The use of Regular continues to decline. Among users of rapid-acting insulin, NovoLog and Humalog have essentially equal market share as of January 2004, at least among visitors to this web site.
Data within rapid-acting insulin only
Data among all responsesLong Acting Insulin Use
In 2004, for the first time, more people report using Lantus than NPH as their long-acting insulin. The use of Lente and Ultralente have declined to almost none. Lantus now shows greater than a 50% market share among users of long-acting insulin.
Data within long-acting insulin only
Data among all responses[Download an Excel spreadsheet with the data and graphs from this poll]
|
|
|||
Last Updated: Wednesday March 16, 2005 15:37:40
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by Children With Diabetes, Inc, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, Privacy Policy, and Safe Harbor Policy.
© Children with Diabetes, Inc. 1995-2013. Comments and Feedback.